Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics.
Antimicrob Steward Healthc Epidemiol
; 2(1): e73, 2022.
Article
in English
| MEDLINE | ID: covidwho-1873362
ABSTRACT
Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
Antimicrob Steward Healthc Epidemiol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS